Clinical Trial: Relative Bioavailability Study of HNC364 Injectable Suspension

U.S., Jan. 30 -- ClinicalTrials.gov registry received information related to the study (NCT06798519) titled 'Relative Bioavailability Study of HNC364 Injectable Suspension' on Jan. 17.

Brief Summary: HNC364 is a new pro-drug of rasagiline as a long-acting injection for deep IM deltoid injection, for the treatment of Parkinson"s disease (PD). As a pro-drug of rasagiline, HNC364 will readily and completely convert to rasagiline after the IM administration.

This is a non-randomized, open-label, Phase 1 study to evaluate the relative bioavailability of HNC364 injectable suspension relative to AZILECT(R) (rasagiline tablets), to assess the safety and tolerability of multiple IM dose HNC364 injectable suspension dose administration in healthy a...